ZMAR is an exchange-traded fund, and unlike a heavily covered stock, it carries no Wall Street analyst price targets. Data providers confirm that no consensus price target or analyst forecast exists for the fund. For that reason, the $32 figure used here is a fallback objective drawn from public discussion of the fund's own design, rather than a broker-dealer consensus. It should not be read as a published forecast.
The logic rests on the fund's annual reset. Innovator's defined-outcome products reset their cap and buffer each March. The current period's cap is 6.73% before fees (5.94% net). If an investor held through a full outcome period, reinvested, and the S&P 500 delivered strong returns in a subsequent period with a similar cap, two consecutive near-cap years would compound a roughly $28.72 starting price toward the low $32 area. The target is therefore best understood as a multi-year compounding scenario, not a one-year expectation.
ZMAR's latest verified market price was about $28.72, near the top of its 52-week range of roughly $27.05 to $28.80. A move to $32 would require an increase of about 11.4%, which is substantial for a fund engineered to cap single-period upside. Notably, the fund was already trading at or near its cap for the current outcome period as of late October 2026, leaving only a low single-digit percentage of additional upside before the February 2027 reset.
The path to $32 is therefore unlikely to be a straight-line advance. It would more plausibly unfold across two or more annual outcome periods, contingent on the reference asset (SPY) continuing to appreciate and on the cap offered at each annual reset remaining near its recent level. Intra-period buyers should also note that the defined outcome only applies in full to shareholders who hold from the start of an outcome period to its end.
The fund's 100% downside buffer is its defining feature. During the current period, the fund seeks to shield investors from the full extent of SPY's price losses, before fees, over the one-year window. That protection can make ZMAR attractive during volatile or uncertain equity markets, supporting steady capital retention that preserves the base from which future gains compound.
Underlying exposure is broad: the fund's FLEX options reference the S&P 500 via SPY, giving large-cap, diversified U.S. equity exposure. Continued large-cap equity strength, positive fund flows (roughly $8.5 million over the trailing year), and the fund's relatively low volatility all support gradual appreciation. Because the cap resets annually, a sequence of positive equity years can produce meaningful compounding even though each individual year is capped.
The upside cap is the primary constraint. With the current cap at 6.73% gross, the fund cannot fully participate in a strong equity rally; its gap to SPY's price return widens whenever the index returns more than the cap. During the current period, the reference asset had returned about 12.5% while the fund had gained only about 3.8%, illustrating how quickly the cap binds.
Other risks include the 0.79% expense ratio, which reduces net returns, and the fact that the buffer applies only if shares are held for the full outcome period; intra-period buyers can experience losses before the buffer engages. Weak or flat equity markets would also limit compounding, and a lower cap at a future annual reset could slow progress toward $32. Finally, the fund is relatively small, with assets under management around $110 million, which can affect liquidity and trading spreads.
ZMAR has traded in a narrow range, with a 52-week low near $27.05 and a high near $28.80. The price sits just below that upper bound, which acts as near-term resistance. Its 50-day moving average was near $28.09 and its 200-day moving average near $27.85, both below the current price, indicating a mildly positive long-term trend structure. A durable support zone sits in the $27.00–$27.50 area near the prior lows. A sustained close above $28.80 would mark a fresh high, while $32 remains well above any level the fund has printed since inception.
Because the $32 objective depends on annual resets, it is best considered over a multi-year horizon rather than a single outcome period. The most important near-term catalyst is the February 28, 2027 outcome-period reset, when Innovator will announce the new cap for the following period. Investors should also track S&P 500 performance, fund flows, changes in the expense ratio or cap levels, and any premium or discount to net asset value. A materially lower cap at reset, or a sustained equity drawdown, would lengthen the path to $32; a higher cap and continued equity gains would shorten it.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. For a capped, low-volatility product like ZMAR, such signals can help traders spot changes in trend and momentum more efficiently than manual chart review. The tool is designed to support discovery of new opportunities, position monitoring, and earlier identification of changing trends. Traders seeking a data-driven edge may find it useful to explore these signals alongside their own research.
Can ZMAR reach $32? The answer depends on time frame and structure. The $32 level is a scenario-based objective, not an analyst consensus, and it implies about 11.4% upside from the current price near $28.72. Because the fund's single-period upside is capped at 6.73% gross, that move is not realistic within one outcome period; it would more plausibly require two or more annual resets with near-cap equity returns. The fund's 100% downside buffer and diversified S&P 500 exposure are meaningful supports, while the cap, the 0.79% expense ratio, and the full-period holding requirement are the principal obstacles. Investors should monitor the February 2027 reset, the new cap level, and equity market direction rather than expect any single-year jump to the target.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that ZMAR and BUFQ have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ZMAR and BUFQ's prices will move in lockstep.
| Ticker / NAME | Correlation To ZMAR | 1D Price Change % | ||
|---|---|---|---|---|
| ZMAR | 100% | -0.04% | ||
| BUFQ - ZMAR | 29% Poorly correlated | -0.49% | ||
| BUFD - ZMAR | 29% Poorly correlated | -0.23% | ||
| FMAY - ZMAR | 27% Poorly correlated | -0.19% | ||
| BUFR - ZMAR | 26% Poorly correlated | -0.19% | ||
| BALT - ZMAR | 26% Poorly correlated | -0.14% | ||
More | ||||